Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
about
Trojan-horse nanotube on-command intracellular drug deliverySynthesis and characterization of perfluoro-tert-butyl semifluorinated amphiphilic polymers and their potential application in hydrophobic drug deliveryA novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety.Neurosteroid 3α-androstanediol efficiently counteracts paclitaxel-induced peripheral neuropathy and painful symptomsCremophor-induced lupus erythematosus-like reaction with taxol administration: a case report and review of the literature.Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapyVIP-targeted Cytotoxic Nanomedicine for Breast CancerThe pharmacological bases of the antiangiogenic activity of paclitaxel.Biodegradable micelles enhance the antiglioma activity of curcumin in vitro and in vivo.Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules.An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation.Macromolecules as taxane delivery systems.A7RC peptide modified paclitaxel liposomes dually target breast cancer.Cellular uptake and antitumour activity of paclitaxel incorporated into trilaurin-based solid lipid nanoparticles in ovarian cancer.Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.Polyelectrolyte multilayer nanoshells with hydrophobic nanodomains for delivery of Paclitaxel.Encapsulation and release of Amphotericin B from an ABC triblock fluorous copolymer.Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.Coadministration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model.
P2860
Q33930095-DAA741F7-5DFF-4E20-B73E-DBCEF04AD818Q34441150-E15CB570-CA98-4633-A56C-0BCE6BB94C21Q34557766-31C8E6BB-E6B7-4B3F-BD2C-5AE5330934D2Q35049356-75F40882-0FBD-440D-AAC5-6749AEC0D44BQ35574188-046D0164-83E4-45AD-BA84-2B2A2D57C440Q36110892-44FB35F4-206D-4C03-803A-E263386E81E1Q36538910-6C439FA1-5868-4478-87B7-34406D76AF97Q36927558-1D2BE29E-1363-4604-85A9-4B8219970EE7Q37003820-9BB1C6AC-4F5D-4049-AFA2-5BE4B396810CQ37293290-B82D3F54-0F48-44FF-9264-AD3099BC22B0Q37652883-F87CB80C-FC96-42C0-A7FA-C97504849279Q37818236-D694A794-E982-42D5-97CF-C510673B14C1Q38842323-4E54AF48-39B8-46E5-BDC9-32A9983A4B2AQ39164588-37ABC9D7-2684-4C54-AF0A-9606088AC978Q39351483-B5942801-FB5A-41B9-A382-998DFC292164Q39397346-11FDD2D1-106B-475D-A00B-989A2CE41877Q39402627-86EEF398-5575-4624-BC8E-0E2ED029413DQ40031682-12A317D4-654A-4162-8EB1-8398297E6281Q47621457-B94367D4-74C5-40A4-97CE-4410A0037344Q47848866-8C81E67E-8209-4AA5-A5C9-92DBBCB07A5C
P2860
Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
@en
Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
@nl
type
label
Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
@en
Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
@nl
prefLabel
Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
@en
Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
@nl
P1476
Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
@en
P2093
Alekha K Dash
Somnath Singh
P304
P356
10.1615/CRITREVTHERDRUGCARRIERSYST.V26.I4.10
P577
2009-01-01T00:00:00Z